lefradafiban + pantoprazole

Lefradafiban + pantoprazole is a **combination drug** consisting of lefradafiban, a reversible oral platelet glycoprotein IIb/IIIa inhibitor (antiplatelet agent), and pantoprazole, a proton pump inhibitor (PPI). Lefradafiban inhibits platelet aggregation by selectively targeting the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and subsequent thrombus formation. This is used in conditions where antiplatelet therapy is indicated, such as acute coronary syndromes. Pantoprazole acts by irreversibly inhibiting the gastric H+/K+-ATPase (proton pump) in parietal cells of the stomach, thereby suppressing the final step of gastric acid production[1][2][3][4][6]. Its main use is for the management and prevention of gastrointestinal disorders including erosive esophagitis, GERD, Zollinger-Ellison syndrome, and protection against NSAID-induced gastric injury. The **combination may be considered to provide simultaneous antiplatelet benefits and gastric protection** for patients requiring both therapies.